APO Research
Talk to an analyst

APO RESEARCH · REPORT

Short-acting Insulin

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Short-acting Insulin Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

29 December 2025196 pages

Choose your research edition.

Industry ResearchShort-acting Insulin Industry Research Report 2026122 pages · $2,950 USDIndustry Growth & TrendsGlobal Short-acting Insulin Industry Growth and Trends Forecast to 2032101 pages · $3,450 USDMarket StructureGlobal Short-acting Insulin Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032196 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Short-acting Insulin Market Outlook and Growth Opportunities 2026195 pages · $4,250 USDMarket Analysis & ForecastGlobal Short-acting Insulin Market Analysis and Forecast 2026-2032199 pages · $4,950 USD

Market perspective

The global Short-acting Insulin market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for Short-acting Insulin is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Short-acting Insulin is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Short-acting Insulin is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Short-acting Insulin is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Short-acting Insulin include Zhuhai United Pharmaceutical, Wanbang Biopharmaceuticals, Sinovac Biotech, HTBT, Tonghua Dongbao Pharmaceutical, Wockhardt, Sanofi, Pfizer and Novo Nordisk, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Short-acting Insulin market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Short-acting Insulin and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Short-acting Insulin sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Short-acting Insulin market size, projected growth trends, production technologies, key applications, and end-use industries.

Short-acting Insulin Segment by Company

Zhuhai United Pharmaceutical

Wanbang Biopharmaceuticals

Sinovac Biotech

HTBT

Tonghua Dongbao Pharmaceutical

Wockhardt

Sanofi

Pfizer

Novo Nordisk

Eli Lilly

Biocon Biologics

Bayer

BASF

Abbott Laboratories

Short-acting Insulin Segment by Type

Regular Insulin

Biosynthetic Human Insulin

Recombinant Human Insulin

Other

Short-acting Insulin Segment by Application

Type 2 Diabetes

Type 1 Diabetes

Gestational Diabetes

Complications of Diabetes

Other

Short-acting Insulin Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Short-acting Insulin market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Short-acting Insulin and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Short-acting Insulin.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Short-acting Insulin market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Short-acting Insulin manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Short-acting Insulin in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Short-acting Insulin in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Short-acting Insulin Industry Trends Table 2. Short-acting Insulin Industry Drivers Table 3. Short-acting Insulin Industry Opportunities and Challenges Table 4. Short-acting Insulin Industry Restraints Table 5. Global Short-acting Insulin Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Short-acting Insulin Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Short-acting Insulin Sales by Manufacturers (K Units) & (2021-2026) Table 8. Global Short-acting Insulin Sales Market Share by Manufacturers Table 9. Global Short-acting Insulin Average Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 10. Global Short-acting Insulin Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Short-acting Insulin Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Short-acting Insulin Manufacturers, Product Type & Application Table 13. Global Short-acting Insulin Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Short-acting Insulin by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of Regular Insulin Table 17. Major Manufacturers of Biosynthetic Human Insulin Table 18. Major Manufacturers of Recombinant Human Insulin Table 19. Major Manufacturers of Other Table 20. Global Short-acting Insulin Sales by Type 2021 VS 2025 VS 2032 (K Units) Table 21. Global Short-acting Insulin Sales by Type (2021-2026) & (K Units) Table 22. Global Short-acting Insulin Sales by Type (2027-2032) & (K Units) Table 23. Global Short-acting Insulin Sales Market Share by Type (2021-2026) Table 24. Global Short-acting Insulin Sales Market Share by Type (2027-2032) Table 25. Global Short-acting Insulin Revenue by Type 2021 VS 2025 VS 2032 (K Units) Table 26. Global Short-acting Insulin Revenue by Type (2021-2026) & (K Units) Table 27. Global Short-acting Insulin Revenue by Type (2027-2032) & (K Units) Table 28. Global Short-acting Insulin Revenue Market Share by Type (2021-2026) Table 29. Global Short-acting Insulin Revenue Market Share by Type (2027-2032) Table 30. Major Manufacturers of Type 2 Diabetes Table 31. Major Manufacturers of Type 1 Diabetes Table 32. Major Manufacturers of Gestational Diabetes Table 33. Major Manufacturers of Complications of Diabetes Table 34. Major Manufacturers of Other Table 35. Global Short-acting Insulin Sales by Application 2021 VS 2025 VS 2032 (K Units) Table 36. Global Short-acting Insulin Sales by Application (2021-2026) & (K Units) Table 37. Global Short-acting Insulin Sales by Application (2027-2032) & (K Units) Table 38. Global Short-acting Insulin Sales Market Share by Application (2021-2026) Table 39. Global Short-acting Insulin Sales Market Share by Application (2027-2032) Table 40. Global Short-acting Insulin Revenue by Application 2021 VS 2025 VS 2032 (K Units) Table 41. Global Short-acting Insulin Revenue by Application (2021-2026) & (K Units) Table 42. Global Short-acting Insulin Revenue by Application (2027-2032) & (K Units) Table 43. Global Short-acting Insulin Revenue Market Share by Application (2021-2026) Table 44. Global Short-acting Insulin Revenue Market Share by Application (2027-2032) Table 45. Global Short-acting Insulin Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 46. Global Short-acting Insulin Sales by Region (2021-2026) & (K Units) Table 47. Global Short-acting Insulin Sales Market Share by Region (2021-2026) Table 48. Global Short-acting Insulin Sales Forecasted by Region (2027-2032) & (K Units) Table 49. Global Short-acting Insulin Sales Forecasted Market Share by Region (2027-2032) Table 50. North America Short-acting Insulin Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 51. North America Short-acting Insulin Sales by Country (2021-2026) & (K Units) Table 52. North America Short-acting Insulin Sales by Country (2027-2032) & (K Units) Table 53. Europe Short-acting Insulin Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 54. Europe Short-acting Insulin Sales by Country (2021-2026) & (K Units) Table 55. Europe Short-acting Insulin Sales by Country (2027-2032) & (K Units) Table 56. Asia Pacific Short-acting Insulin Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 57. Asia Pacific Short-acting Insulin Sales by Country (2021-2026) & (K Units) Table 58. Asia Pacific Short-acting Insulin Sales by Country (2027-2032) & (K Units) Table 59. South America, Middle East and Africa Short-acting Insulin Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 60. South America, Middle East and Africa Short-acting Insulin Sales by Country (2021-2026) & (K Units) Table 61. South America, Middle East and Africa Short-acting Insulin Sales by Country (2027-2032) & (K Units) Table 62. Global Short-acting Insulin Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 63. Global Short-acting Insulin Revenue by Region (2021-2026) & (US$ Million) Table 64. Global Short-acting Insulin Revenue by Region (2027-2032) & (US$ Million) Table 65. Global Short-acting Insulin Revenue Market Share by Region (2021-2026) Table 66. Global Short-acting Insulin Revenue Market Share by Region (2027-2032) Table 67. Zhuhai United Pharmaceutical Company Information Table 68. Zhuhai United Pharmaceutical Business Overview Table 69. Zhuhai United Pharmaceutical Short-acting Insulin Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 70. Zhuhai United Pharmaceutical Short-acting Insulin Product Portfolio Table 71. Zhuhai United Pharmaceutical Recent Development Table 72. Wanbang Biopharmaceuticals Company Information Table 73. Wanbang Biopharmaceuticals Business Overview Table 74. Wanbang Biopharmaceuticals Short-acting Insulin Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 75. Wanbang Biopharmaceuticals Short-acting Insulin Product Portfolio Table 76. Wanbang Biopharmaceuticals Recent Development Table 77. Sinovac Biotech Company Information Table 78. Sinovac Biotech Business Overview Table 79. Sinovac Biotech Short-acting Insulin Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 80. Sinovac Biotech Short-acting Insulin Product Portfolio Table 81. Sinovac Biotech Recent Development Table 82. HTBT Company Information Table 83. HTBT Business Overview Table 84. HTBT Short-acting Insulin Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 85. HTBT Short-acting Insulin Product Portfolio Table 86. HTBT Recent Development Table 87. Tonghua Dongbao Pharmaceutical Company Information Table 88. Tonghua Dongbao Pharmaceutical Business Overview Table 89. Tonghua Dongbao Pharmaceutical Short-acting Insulin Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 90. Tonghua Dongbao Pharmaceutical Short-acting Insulin Product Portfolio Table 91. Tonghua Dongbao Pharmaceutical Recent Development Table 92. Wockhardt Company Information Table 93. Wockhardt Business Overview Table 94. Wockhardt Short-acting Insulin Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 95. Wockhardt Short-acting Insulin Product Portfolio Table 96. Wockhardt Recent Development Table 97. Sanofi Company Information Table 98. Sanofi Business Overview Table 99. Sanofi Short-acting Insulin Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 100. Sanofi Short-acting Insulin Product Portfolio Table 101. Sanofi Recent Development Table 102. Pfizer Company Information Table 103. Pfizer Business Overview Table 104. Pfizer Short-acting Insulin Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 105. Pfizer Short-acting Insulin Product Portfolio Table 106. Pfizer Recent Development Table 107. Novo Nordisk Company Information Table 108. Novo Nordisk Business Overview Table 109. Novo Nordisk Short-acting Insulin Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 110. Novo Nordisk Short-acting Insulin Product Portfolio Table 111. Novo Nordisk Recent Development Table 112. Eli Lilly Company Information Table 113. Eli Lilly Business Overview Table 114. Eli Lilly Short-acting Insulin Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 115. Eli Lilly Short-acting Insulin Product Portfolio Table 116. Eli Lilly Recent Development Table 117. Biocon Biologics Company Information Table 118. Biocon Biologics Business Overview Table 119. Biocon Biologics Short-acting Insulin Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 120. Biocon Biologics Short-acting Insulin Product Portfolio Table 121. Biocon Biologics Recent Development Table 122. Bayer Company Information Table 123. Bayer Business Overview Table 124. Bayer Short-acting Insulin Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 125. Bayer Short-acting Insulin Product Portfolio Table 126. Bayer Recent Development Table 127. BASF Company Information Table 128. BASF Business Overview Table 129. BASF Short-acting Insulin Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 130. BASF Short-acting Insulin Product Portfolio Table 131. BASF Recent Development Table 132. Abbott Laboratories Company Information Table 133. Abbott Laboratories Business Overview Table 134. Abbott Laboratories Short-acting Insulin Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 135. Abbott Laboratories Short-acting Insulin Product Portfolio Table 136. Abbott Laboratories Recent Development Table 137. Key Raw Materials Table 138. Raw Materials Key Suppliers Table 139. Short-acting Insulin Distributors List Table 140. Short-acting Insulin Customers List Table 141. Research Programs/Design for This Report Table 142. Authors List of This Report Table 143. Secondary Sources Table 144. Primary Sources List of Figures Figure 1. Short-acting Insulin Product Image Figure 2. Global Short-acting Insulin Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Short-acting Insulin Market Size (2021-2032) & (US$ Million) Figure 4. Global Short-acting Insulin Sales (2021-2032) & (K Units) Figure 5. Global Short-acting Insulin Average Price (US$/Unit) & (2021-2032) Figure 6. Global Top 5 and 10 Short-acting Insulin Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. Regular Insulin Image Figure 9. Biosynthetic Human Insulin Image Figure 10. Recombinant Human Insulin Image Figure 11. Other Image Figure 12. Global Short-acting Insulin Sales by Type (2021 VS 2025 VS 2032) & (K Units) Figure 13. Global Short-acting Insulin Sales Market Share 2021 VS 2025 VS 2032 Figure 14. Global Short-acting Insulin Sales Market Share by Type (2021-2032) Figure 15. Global Short-acting Insulin Revenue by Type (2021 VS 2025 VS 2032) & (K Units) Figure 16. Global Short-acting Insulin Revenue Market Share 2021 VS 2025 VS 2032 Figure 17. Global Short-acting Insulin Revenue Market Share by Type (2021-2032) Figure 18. Type 2 Diabetes Image Figure 19. Type 1 Diabetes Image Figure 20. Gestational Diabetes Image Figure 21. Complications of Diabetes Image Figure 22. Other Image Figure 23. Global Short-acting Insulin Sales by Application (2021 VS 2025 VS 2032) & (K Units) Figure 24. Global Short-acting Insulin Sales Market Share 2021 VS 2025 VS 2032 Figure 25. Global Short-acting Insulin Sales Market Share by Application (2021-2032) Figure 26. Global Short-acting Insulin Revenue by Application (2021 VS 2025 VS 2032) & (K Units) Figure 27. Global Short-acting Insulin Revenue Market Share 2021 VS 2025 VS 2032 Figure 28. Global Short-acting Insulin Revenue Market Share by Application (2021-2032) Figure 29. North America Short-acting Insulin Sales and Growth Rate (2021-2032) & (K Units) Figure 30. North America Short-acting Insulin Sales Market Share by Country (2021-2032) Figure 31. U.S. Short-acting Insulin Sales and Growth Rate (2021-2032) & (K Units) Figure 32. Canada Short-acting Insulin Sales and Growth Rate (2021-2032) & (K Units) Figure 33. Mexico Short-acting Insulin Sales and Growth Rate (2021-2032) & (K Units) Figure 34. Europe Short-acting Insulin Sales and Growth Rate (2021-2032) & (K Units) Figure 35. Europe Short-acting Insulin Sales Market Share by Country (2021-2032) Figure 36. Germany Short-acting Insulin Sales and Growth Rate (2021-2032) & (K Units) Figure 37. France Short-acting Insulin Sales and Growth Rate (2021-2032) & (K Units) Figure 38. U.K. Short-acting Insulin Sales and Growth Rate (2021-2032) & (K Units) Figure 39. Italy Short-acting Insulin Sales and Growth Rate (2021-2032) & (K Units) Figure 40. Netherlands Short-acting Insulin Sales and Growth Rate (2021-2032) & (K Units) Figure 41. Asia Pacific Short-acting Insulin Sales and Growth Rate (2021-2032) & (K Units) Figure 42. Asia Pacific Short-acting Insulin Sales Market Share by Country (2021-2032) Figure 43. China Short-acting Insulin Sales and Growth Rate (2021-2032) & (K Units) Figure 44. Japan Short-acting Insulin Sales and Growth Rate (2021-2032) & (K Units) Figure 45. South Korea Short-acting Insulin Sales and Growth Rate (2021-2032) & (K Units) Figure 46. Southeast Asia Short-acting Insulin Sales and Growth Rate (2021-2032) & (K Units) Figure 47. India Short-acting Insulin Sales and Growth Rate (2021-2032) & (K Units) Figure 48. Australia Short-acting Insulin Sales and Growth Rate (2021-2032) & (K Units) Figure 49. South America, Middle East and Africa Short-acting Insulin Sales and Growth Rate (2021-2032) & (K Units) Figure 50. South America, Middle East and Africa Short-acting Insulin Sales Market Share by Country (2021-2032) Figure 51. Brazil Short-acting Insulin Sales and Growth Rate (2021-2032) & (K Units) Figure 52. South Africa Short-acting Insulin Sales and Growth Rate (2021-2032) & (K Units) Figure 53. Saudi Arabia Short-acting Insulin Sales and Growth Rate (2021-2032) & (K Units) Figure 54. Turkey Short-acting Insulin Sales and Growth Rate (2021-2032) & (K Units) Figure 55. Argentina Short-acting Insulin Sales and Growth Rate (2021-2032) & (K Units) Figure 56. UAE Short-acting Insulin Sales and Growth Rate (2021-2032) & (K Units) Figure 57. Egypt Short-acting Insulin Sales and Growth Rate (2021-2032) & (K Units) Figure 58. Chile Short-acting Insulin Sales and Growth Rate (2021-2032) & (K Units) Figure 59. Global Short-acting Insulin Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 60. Global Short-acting Insulin Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 61. North America Short-acting Insulin Revenue (2021-2032) & (US$ Million) Figure 62. North America Short-acting Insulin Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 63. Europe Short-acting Insulin Revenue (2021-2032) & (US$ Million) Figure 64. Europe Short-acting Insulin Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 65. Asia-Pacific Short-acting Insulin Revenue (2021-2032) & (US$ Million) Figure 66. Asia-Pacific Short-acting Insulin Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 67. South America, Middle East and Africa Short-acting Insulin Revenue (2021-2032) & (US$ Million) Figure 68. South America, Middle East and Africa Short-acting Insulin Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 69. Short-acting Insulin Value Chain Figure 70. Manufacturing Cost Structure Figure 71. Short-acting Insulin Production Mode & Process Figure 72. Direct Comparison with Distribution Share Figure 73. Distributors Profiles Figure 74. Years Considered Figure 75. Research Process Figure 76. Key Executives Interviewed

Scope & coverage.

Types
  • Regular Insulin
  • Biosynthetic Human Insulin
  • Recombinant Human Insulin
  • Other
Applications
  • Type 2 Diabetes
  • Type 1 Diabetes
  • Gestational Diabetes
  • Complications of Diabetes
  • Other
Companies covered
  • Zhuhai United Pharmaceutical
  • Wanbang Biopharmaceuticals
  • Sinovac Biotech
  • HTBT
  • Tonghua Dongbao Pharmaceutical
  • Wockhardt
  • Sanofi
  • Pfizer
  • Novo Nordisk
  • Eli Lilly
  • Biocon Biologics
  • Bayer
  • BASF
  • Abbott Laboratories

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Short-acting Insulin Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Short-acting Insulin Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Short-acting Insulin Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Short-acting Insulin Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Short-acting Insulin Market Dynamics
  1. 2.1 Short-acting Insulin Industry Trends
  2. 2.2 Short-acting Insulin Industry Drivers
  3. 2.3 Short-acting Insulin Industry Opportunities and Challenges
  4. 2.4 Short-acting Insulin Industry Restraints
3 Short-acting Insulin Market by Manufacturers
  1. 3.1 Global Short-acting Insulin Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Short-acting Insulin Sales by Manufacturers (2021-2026)
  3. 3.3 Global Short-acting Insulin Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Short-acting Insulin Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Short-acting Insulin Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Short-acting Insulin Manufacturers, Product Type & Application
  7. 3.7 Global Short-acting Insulin Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Short-acting Insulin Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Short-acting Insulin Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Short-acting Insulin Tier 1, Tier 2, and Tier 3
4 Short-acting Insulin Market by Type
  1. 4.1 Short-acting Insulin Type Introduction
  2. 4.1.1 Regular Insulin
  3. 4.1.2 Biosynthetic Human Insulin
  4. 4.1.3 Recombinant Human Insulin
  5. 4.1.4 Other
  6. 4.2 Global Short-acting Insulin Sales by Type
  7. 4.2.1 Global Short-acting Insulin Sales by Type (2021 VS 2025 VS 2032)
  8. 4.2.2 Global Short-acting Insulin Sales by Type (2021-2032)
  9. 4.2.3 Global Short-acting Insulin Sales Market Share by Type (2021-2032)
  10. 4.3 Global Short-acting Insulin Revenue by Type
  11. 4.3.1 Global Short-acting Insulin Revenue by Type (2021 VS 2025 VS 2032)
  12. 4.3.2 Global Short-acting Insulin Revenue by Type (2021-2032)
  13. 4.3.3 Global Short-acting Insulin Revenue Market Share by Type (2021-2032)
5 Short-acting Insulin Market by Application
  1. 5.1 Short-acting Insulin Application Introduction
  2. 5.1.1 Type 2 Diabetes
  3. 5.1.2 Type 1 Diabetes
  4. 5.1.3 Gestational Diabetes
  5. 5.1.4 Complications of Diabetes
  6. 5.1.5 Other
  7. 5.2 Global Short-acting Insulin Sales by Application
  8. 5.2.1 Global Short-acting Insulin Sales by Application (2021 VS 2025 VS 2032)
  9. 5.2.2 Global Short-acting Insulin Sales by Application (2021-2032)
  10. 5.2.3 Global Short-acting Insulin Sales Market Share by Application (2021-2032)
  11. 5.3 Global Short-acting Insulin Revenue by Application
  12. 5.3.1 Global Short-acting Insulin Revenue by Application (2021 VS 2025 VS 2032)
  13. 5.3.2 Global Short-acting Insulin Revenue by Application (2021-2032)
  14. 5.3.3 Global Short-acting Insulin Revenue Market Share by Application (2021-2032)
6 Global Short-acting Insulin Sales by Region
  1. 6.1 Global Short-acting Insulin Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Short-acting Insulin Sales by Region (2021-2032)
  3. 6.2.1 Global Short-acting Insulin Sales by Region (2021-2026)
  4. 6.2.2 Global Short-acting Insulin Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Short-acting Insulin Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Short-acting Insulin Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Short-acting Insulin Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Short-acting Insulin Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Short-acting Insulin Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Short-acting Insulin Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Short-acting Insulin Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Short-acting Insulin Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Short-acting Insulin Revenue by Region
  1. 7.1 Global Short-acting Insulin Revenue by Region
  2. 7.1.1 Global Short-acting Insulin Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Short-acting Insulin Revenue by Region (2021-2026)
  4. 7.1.3 Global Short-acting Insulin Revenue by Region (2027-2032)
  5. 7.1.4 Global Short-acting Insulin Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Short-acting Insulin Revenue (2021-2032)
  8. 7.2.2 North America Short-acting Insulin Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Short-acting Insulin Revenue (2021-2032)
  11. 7.3.2 Europe Short-acting Insulin Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Short-acting Insulin Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Short-acting Insulin Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Short-acting Insulin Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Short-acting Insulin Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 Zhuhai United Pharmaceutical
  2. 8.1.1 Zhuhai United Pharmaceutical Company Information
  3. 8.1.2 Zhuhai United Pharmaceutical Business Overview
  4. 8.1.3 Zhuhai United Pharmaceutical Short-acting Insulin Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Zhuhai United Pharmaceutical Short-acting Insulin Product Portfolio
  6. 8.1.5 Zhuhai United Pharmaceutical Recent Developments
  7. 8.2 Wanbang Biopharmaceuticals
  8. 8.2.1 Wanbang Biopharmaceuticals Company Information
  9. 8.2.2 Wanbang Biopharmaceuticals Business Overview
  10. 8.2.3 Wanbang Biopharmaceuticals Short-acting Insulin Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Wanbang Biopharmaceuticals Short-acting Insulin Product Portfolio
  12. 8.2.5 Wanbang Biopharmaceuticals Recent Developments
  13. 8.3 Sinovac Biotech
  14. 8.3.1 Sinovac Biotech Company Information
  15. 8.3.2 Sinovac Biotech Business Overview
  16. 8.3.3 Sinovac Biotech Short-acting Insulin Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Sinovac Biotech Short-acting Insulin Product Portfolio
  18. 8.3.5 Sinovac Biotech Recent Developments
  19. 8.4 HTBT
  20. 8.4.1 HTBT Company Information
  21. 8.4.2 HTBT Business Overview
  22. 8.4.3 HTBT Short-acting Insulin Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 HTBT Short-acting Insulin Product Portfolio
  24. 8.4.5 HTBT Recent Developments
  25. 8.5 Tonghua Dongbao Pharmaceutical
  26. 8.5.1 Tonghua Dongbao Pharmaceutical Company Information
  27. 8.5.2 Tonghua Dongbao Pharmaceutical Business Overview
  28. 8.5.3 Tonghua Dongbao Pharmaceutical Short-acting Insulin Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Tonghua Dongbao Pharmaceutical Short-acting Insulin Product Portfolio
  30. 8.5.5 Tonghua Dongbao Pharmaceutical Recent Developments
  31. 8.6 Wockhardt
  32. 8.6.1 Wockhardt Company Information
  33. 8.6.2 Wockhardt Business Overview
  34. 8.6.3 Wockhardt Short-acting Insulin Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Wockhardt Short-acting Insulin Product Portfolio
  36. 8.6.5 Wockhardt Recent Developments
  37. 8.7 Sanofi
  38. 8.7.1 Sanofi Company Information
  39. 8.7.2 Sanofi Business Overview
  40. 8.7.3 Sanofi Short-acting Insulin Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Sanofi Short-acting Insulin Product Portfolio
  42. 8.7.5 Sanofi Recent Developments
  43. 8.8 Pfizer
  44. 8.8.1 Pfizer Company Information
  45. 8.8.2 Pfizer Business Overview
  46. 8.8.3 Pfizer Short-acting Insulin Sales, Price, Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Pfizer Short-acting Insulin Product Portfolio
  48. 8.8.5 Pfizer Recent Developments
  49. 8.9 Novo Nordisk
  50. 8.9.1 Novo Nordisk Company Information
  51. 8.9.2 Novo Nordisk Business Overview
  52. 8.9.3 Novo Nordisk Short-acting Insulin Sales, Price, Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Novo Nordisk Short-acting Insulin Product Portfolio
  54. 8.9.5 Novo Nordisk Recent Developments
  55. 8.10 Eli Lilly
  56. 8.10.1 Eli Lilly Company Information
  57. 8.10.2 Eli Lilly Business Overview
  58. 8.10.3 Eli Lilly Short-acting Insulin Sales, Price, Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Eli Lilly Short-acting Insulin Product Portfolio
  60. 8.10.5 Eli Lilly Recent Developments
  61. 8.11 Biocon Biologics
  62. 8.11.1 Biocon Biologics Company Information
  63. 8.11.2 Biocon Biologics Business Overview
  64. 8.11.3 Biocon Biologics Short-acting Insulin Sales, Price, Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Biocon Biologics Short-acting Insulin Product Portfolio
  66. 8.11.5 Biocon Biologics Recent Developments
  67. 8.12 Bayer
  68. 8.12.1 Bayer Company Information
  69. 8.12.2 Bayer Business Overview
  70. 8.12.3 Bayer Short-acting Insulin Sales, Price, Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Bayer Short-acting Insulin Product Portfolio
  72. 8.12.5 Bayer Recent Developments
  73. 8.13 BASF
  74. 8.13.1 BASF Company Information
  75. 8.13.2 BASF Business Overview
  76. 8.13.3 BASF Short-acting Insulin Sales, Price, Revenue and Gross Margin (2021-2026)
  77. 8.13.4 BASF Short-acting Insulin Product Portfolio
  78. 8.13.5 BASF Recent Developments
  79. 8.14 Abbott Laboratories
  80. 8.14.1 Abbott Laboratories Company Information
  81. 8.14.2 Abbott Laboratories Business Overview
  82. 8.14.3 Abbott Laboratories Short-acting Insulin Sales, Price, Revenue and Gross Margin (2021-2026)
  83. 8.14.4 Abbott Laboratories Short-acting Insulin Product Portfolio
  84. 8.14.5 Abbott Laboratories Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Short-acting Insulin Value Chain Analysis
  2. 9.1.1 Short-acting Insulin Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Short-acting Insulin Production Mode & Process
  6. 9.2 Short-acting Insulin Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Short-acting Insulin Distributors
  9. 9.2.3 Short-acting Insulin Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst